Anthropic Reveals Claude Drug Discovery Progress: 35k Antibodies, Clinical Trials by 2028

Anthropic has disclosed significant breakthroughs in drug discovery using its AI model Claude, announcing deep collaborations with six biopharma firms and initiating internal clinical trial plans. Key achievements include generating approximately 35,000 antibody designs in one month, drastically improving early-stage screening efficiency, and identifying seven critical production issues missed by human reviewers, demonstrating superior quality control capabilities.

Cross-verified reports indicate Claude's application spans the entire R&D cycle, from molecular design and CAR-T gene sequence optimization to regulatory document review, reducing review time by 90%. Anthropic also acquired Mithril Medicine, a micro-pharma company operated independently by AI, to validate autonomous operational potential in contracts, logistics, and experiment coordination. While most projects remain in preclinical or animal testing stages, an internal project targeting muscular dystrophy is expected to enter human clinical trials as early as late 2028.

This progress marks a shift of AI from an auxiliary tool to a core driver in drug development. By showcasing quantifiable efficiency gains and automation cases, Anthropic strengthens its commercial narrative in life sciences and provides a reproducible path for AI-accelerated drug discovery, signaling that AI-native drugs are moving toward clinical validation.